Literature DB >> 3941402

Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats.

D E Gmerek, A Cowan, J H Woods.   

Abstract

The individual contributions of central (brain) and peripheral (enteric) sites in the mediation of the systemic actions of opioids are not well established. In this study, we made use of naltrexone methobromide, a quaternary analog of naltrexone, to separate the central and peripheral components of the slowing action of morphine on gastrointestinal transit in rats. It was established that i.c.v., but not s.c., administration of quaternary naltrexone antagonized morphine-induced analgesia in the radiant-heat tail-flick assay in rats. Thus, quaternary naltrexone probably does not enter the central nervous system in significant amounts after systemic administration. Systemic quaternary naltrexone antagonized, in a dose-related manner, the delaying effects of morphine on the movement of a charcoal meal along the gastrointestinal tract. Quaternary naltrexone was 30 or 100 times less potent than naltrexone when administered s.c. or i.c.v., respectively. Unlike naltrexone, quaternary naltrexone antagonized morphine-induced slowing of gastrointestinal transit only when administered by the same route (i.e., both s.c. or both i.c.v.). The apparent pA2 for s.c. quaternary naltrexone against s.c. morphine was not significantly different from the apparent pA2 for i.c.v. quaternary naltrexone against i.c.v. morphine. Distinct and independent central and peripheral systems appear to mediate morphine-induced inhibition of gastrointestinal transit in rats. However, the receptors are probably of the same type. Peripherally selective antagonists such as quaternary naltrexone may be useful in reversing morphine-induced inhibition of gastrointestinal transit without affecting analgesia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3941402

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone.

Authors:  Antonio Gatti; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2012-05-01       Impact factor: 2.859

2.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

3.  Effects of repeated morphine on ultrasonic vocalizations in adult rats: increased 50-kHz call rate and altered subtype profile.

Authors:  Laura M Best; Leah L Zhao; Tina Scardochio; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2016-10-11       Impact factor: 4.530

4.  Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.

Authors:  M Hiramatsu; K Inoue; A Ambo; Y Sasaki; T Kameyama
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 5.  Methylnaltrexone.

Authors:  Karly P Garnock-Jones; Kate McKeage
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

6.  6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.

Authors:  Yunyun Yuan; David L Stevens; Amanda Braithwaite; Krista L Scoggins; Edward J Bilsky; Hamid I Akbarali; William L Dewey; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2012-05-26       Impact factor: 2.823

7.  Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus.

Authors:  Kalina Venkova; Graeme Fraser; Hamid R Hoveyda; Beverley Greenwood-Van Meerveld
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.199

8.  Effect of pretreatment with pertussis toxin on the development of physical dependence on morphine.

Authors:  M Funada; M Narita; T Suzuki; M Misawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

Review 9.  Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.

Authors:  Andrea Kurz; Daniel I Sessler
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Protease inhibitor-induced nausea and vomiting is attenuated by a peripherally acting, opioid-receptor antagonist in a rat model.

Authors:  Chun-Su Yuan; Chong-Zhi Wang; Sangeeta R Mehendale; Han H Aung; Adela Foo; Robert J Israel
Journal:  AIDS Res Ther       Date:  2009-08-21       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.